Latest Breaking News On - Bruce mackle - Page 5 : comparemela.com

BioAtla, Inc (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript

Operator: Greetings and welcome to the BioAtla Fourth Quarter and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.

United statesRichard waldronKelly shiBruce mackleKaveri pohlmanEric sieversSheri lydickBioatla incCall transcript marchBioatla fourth quarterFull yearJay shortChief financialChief medical officerChief commercial officerRare cancers

SELLAS Life Sciences Group, Inc : SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

SELLAS Life Sciences Group, Inc : SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Angelos stergiouBruce mackleDennis riedlSteering committee guided interim analysis imminentSteering committeeMemorial sloan kettering cancer centerCompany to host corporate update webinarLifesci advisorsLife sciences group incGenfleet therapeutics shanghai incEnrollment completedLate aprilResponse rateSelected optimal doseIdentified biomarkersNot been reached

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bruce mackleAngelos stergiouGenfleet therapeutics shanghai incSteering committee guided interim analysis imminentLife sciences group incSteering committeeLifesci advisorsMemorial sloan kettering cancer centerCompany to host corporate update webinarEnrollment completedLate aprilResponse rateSelected optimal doseIdentified biomarkersNot been reachedRemains leukemia free

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-s.

United statesBruce mackleExchange commissionReviva pharmaceuticalsAmerican society for clinical pharmacology therapeuticsSecurities exchangeReviva pharmaceuticals holdings incLifesci advisorsPharmaceuticals holdingsLaxminarayan bhatAmerican societyClinical pharmacologyColorado springsBrilaroxazine efficacyOrphan drug designationSecurities act

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April-

Bruce mackleAngelos stergiouSteering committeeGenfleet therapeutics shanghai incLifesci advisorsSteering committee guided interim analysis imminentCompany to host corporate update webinarLife sciences group incMemorial sloan kettering cancer centerEnrollment completedResponse rateSelected optimal doseIdentified biomarkersNot been reachedRemains leukemia freeStrong anti leukemic activity